Phathom Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share (PHAT)

Historical Holders from Q4 2019 to Q3 2025

Symbol
PHAT on Nasdaq
Type / Class
Equity / Common Stock, $0.0001 par value per share
Shares outstanding
69.6M
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares, excl. options
62.3M
Holdings value
$734M
% of all portfolios
0.002%
Grand Portfolio weight change
+0%
Number of holders
132
Number of buys
70
Number of sells
-39
Average Value change %
0%
Average buys %
+0.001%
Average sells %
-0.001%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Phathom Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share (PHAT)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Frazier Life Sciences Public Fund, L.P. 8.6% 0% $70.4M 5.99M 0% James N. Topper 01 Nov 2025
MILLENNIUM MANAGEMENT LLC 7.1% +20% $59.8M $10.8M 5.08M +22.1% Millennium Management LLC 30 Sep 2025
Carlyle Group Inc. 4.9% $30.1M 3.5M Carlyle Group Inc. 28 Aug 2025
BlackRock, Inc. 4.6% $14.1M 3.23M BlackRock, Inc. 31 Mar 2025
PRUDENTIAL FINANCIAL INC 0% -100% $8.71K -$24.5M 2.63K -100% PRUDENTIAL FINANCIAL INC 31 May 2025

Institutional Holders of Phathom Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share (PHAT)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 62.3M $734M +$59M $11.77 132
2025 Q2 57.4M $551M -$26.7M $9.59 117
2025 Q1 64M $401M -$24.9M $6.27 136
2024 Q4 66.6M $541M -$121M $8.12 141
2024 Q3 72.6M $1.31B +$264M $18.08 133
2024 Q2 58.1M $599M +$27.9M $10.30 113
2024 Q1 55.4M $588M +$14.6M $10.62 112
2023 Q4 54.1M $503M +$11.4M $9.13 115
2023 Q3 43.8M $453M +$5.27M $10.37 109
2023 Q2 42.8M $613M +$176M $14.32 103
2023 Q1 30.8M $220M +$28.3M $7.14 83
2022 Q4 28.2M $317M -$21.7M $11.22 83
2022 Q3 30.2M $334M +$38M $11.08 87
2022 Q2 27.3M $230M +$9.34M $8.44 88
2022 Q1 25.7M $349M -$176M $13.61 74
2021 Q4 28.6M $562M +$49.9M $19.67 82
2021 Q3 25.5M $820M +$19.2M $32.10 81
2021 Q2 24.9M $844M +$13.2M $33.85 76
2021 Q1 24.5M $919M +$1.76M $37.56 82
2020 Q4 24.5M $815M +$96.7M $33.22 75
2020 Q3 21.6M $794M -$7.64M $36.67 57
2020 Q2 21.8M $719M -$3.03M $32.91 59
2020 Q1 21.9M $566M +$3.22M $25.82 47
2019 Q4 21.8M $677M +$593M $31.14 40